- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
FILING NO. 2 FOR THE MONTH OF JULY, 2001
VISIBLE GENETICS INC.
(Exact name of Registrant)
700 BAY STREET, SUITE 1000, TORONTO ON, CANADA M5G 1Z6
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F
--- ---
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
--- ---
- --------------------------------------------------------------------------------
VISIBLE GENETICS INC.
On July 26, 2001, we announced that Dr. Brendan Larder is to join Visible
Genetics as its new Chief Scientific Officer ("CSO"). In his role as CSO, Dr.
Larder will be responsible for all research activities in our company including
programs involving both existing and new assays, advanced technology platforms
for genetic and mutational analysis, and bioinformatic interpretation systems in
a variety of disease areas.
From 1985 to 1997, Dr. Larder was a research scientist at the Wellcome
Research Laboratories in London. Since 1997, Dr. Larder has been the Chief
Scientific Officer at VIRCO. Dr. Larder has been a leading researcher in the HIV
drug resistance area for over 15 years and has published numerous seminal
publications in this field. Best known for his discovery of HIV drug resistance
and the genetic mechanisms that underlie it, Dr. Larder pioneered many of the
technologies that are in use today to monitor drug resistance in the clinic.
This Form 6-K may contain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause our results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and our products, delays in, or the
refusal of, insurance companies and other third-party payors to reimburse us for
our products, delays in product development, delays in making the new Atlanta
manufacturing facility operational, and other risks detailed from time to time
in our SEC filings, including our most recent Annual Report on Form 20-F. These
forward-looking statements speak only as of the date hereof. We disclaim any
intent or obligation to update these forward-looking statements.
We hereby incorporate by reference the text of this Form 6-K, but not the
Exhibit attached hereto, into our Registration Statements on Form F-3, and into
the prospectuses contained therein, (File Nos. 333-67607, 333-68939, 333-91155,
333-94649 and 333-40616) and our outstanding Registration Statements on Form S-8
and into the reoffer prospectuses contained therein.
Exhibit 1. Press Release dated July 26, 2001
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: July 26, 2001 By: /s/ Thomas J. Clarke
--------------------
Name: Thomas J. Clarke
Title: Chief Financial Officer